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Abstract
 
Recently, biochemical, cell biological, and genetic studies have converged to reveal that inte-
gral membrane heparan sulfate proteoglycans (HSPGs) are critical regulators of growth and dif-
ferentiation of epithelial and connective tissues. As a large number of cytokines involved in
lymphoid tissue homeostasis or inflammation contain potential HS-binding domains, HSPGs
presumably also play important roles in the regulation of the immune response. In this report,
we explored the expression, regulation, and function of HSPGs on B lymphocytes. We dem-
onstrate that activation of the B cell antigen receptor (BCR) and/or CD40 induces a strong
transient expression of HSPGs on human tonsillar B cells. By means of these HSPGs, the acti-
 
vated B cells can bind hepatocyte growth factor (HGF), a cytokine that regulates integrin-
mediated B cell adhesion and migration. This interaction with HGF is highly selective since
 
the HSPGs did not bind the chemokine stromal cell–derived factor (SDF)-1
 
a
 
, even though the
affinities of HGF and SDF-1
 
a
 
 for heparin are similar. On the activated B cells, we observed in-
duction of a specific HSPG isoform of CD44 (CD44-HS), but not of other HSPGs such as
syndecans or glypican-1. Interestingly, the expression of CD44-HS on B cells strongly pro-
motes HGF-induced signaling, resulting in an HS-dependent enhanced phosphorylation of
Met, the receptor tyrosine kinase for HGF, as well as downstream signaling molecules includ-
ing Grb2-associated binder 1 (Gab1) and Akt/protein kinase B (PKB). Our results demonstrate
that the BCR and CD40 control the expression of HSPGs, specifically CD44-HS. These
HSPGs act as functional coreceptors that selectively promote cytokine signaling in B cells, sug-
gesting a dynamic role for HSPGs in antigen-specific B cell differentiation.
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Introduction
 
Proteoglycans are proteins that are covalently linked to sul-
 
fated glycosaminoglycan (GAG)
 
1
 
 chains composed of re-
peating disaccharide units (1). These molecules, which are
widespread throughout mammalian tissues as extracellular
matrix components and membrane-bound molecules, have
been implicated in several important biological processes
including cell adhesion and migration, angiogenesis, tissue
morphogenesis, and regulation of blood coagulation (1–3).
In these processes, proteoglycans are believed to function as
scaffold structures, designed to accommodate proteins
through noncovalent binding to their GAG chains. In par-
ticular, heparan sulfate proteoglycans (HSPGs) have been
shown to function as versatile protein coreceptors. Their
ligand-binding sites reside within discrete sulfated domains
formed by complex, cell-specific, chemical modifications
of the HS disaccharide repeat (4). Binding of proteins, in-
cluding growth factors/cytokines, to HS chains may serve a
variety of functions ranging from immobilization and con-
centration, to distinct modulation of biological function (5,
6). This functional importance is illustrated by fibroblast
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Abbreviations used in this paper:
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blast growth factor; Gab1, Grb2-associated binder 1; GAG, glycosami-
noglycan; GC, germinal center; HGF, hepatocyte growth factor; HS,
heparan sulfate; HSPG, HS proteoglycan; PKB, protein kinase B; SAC,
 
Staphylococcus aureus
 
 Cowan strain I; SDF, stromal cell-derived factor. 
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growth factor (FGF)-2, whose binding to its signal-trans-
ducing receptors and consequent biological effects are criti-
cally dependent on its interaction with cell surface HSPGs
(7, 8). Recently, several cell biological and genetic studies
have provided compelling evidence for an in vivo role of
cell surface HSPGs in growth control and morphogenesis
in 
 
Drosophila
 
, mice, and humans (9–14).
Most studies concerning the expression and function of
cell surface HSPGs have focussed on epithelial cells and
fibroblasts, but these molecules presumably also play im-
portant roles in the immune system. A vast number of cy-
tokines involved in lymphoid tissue homeostasis or inflam-
mation bind to heparin, a GAG structurally related to HS.
These cytokines, which include chemokines as well as in-
terleukins and hematopoietic growth factors, e.g., IL-3, IL-
8, GM-CSF, and hepatocyte growth factor (HGF) (15–20),
can thus be potentially immobilized by HSPGs. HSPGs ex-
pressed on the luminal surface of endothelial cells have
been shown to bind chemokines produced at sites of in-
flammation (21), thereby preventing their immediate dilu-
tion by the blood stream. Presentation of HSPG-bound
chemokines, e.g., macrophage inflammatory protein 1
 
b
 
and IL-8, to leukocytes plays a crucial role in activating the
leukocyte integrins that mediate stable adhesion to and
transmigration across the vessel wall (22, 23). However,
chemokines and other heparin-binding cytokines do not
exclusively act at the endothelial–blood interface. They
also play key roles in the regulation of lymphocyte traffick-
ing within lymphoid tissues and are involved in the control
of lymphocyte growth, differentiation, and survival (24).
This suggests that cell surface HSPGs on cells of the im-
mune system, such as lymphocytes and antigen-presenting
cells, might also be involved in the regulation of cytokine
responsiveness. To explore this hypothesis, we have studied
the expression, identity, regulation, and function of HSPGs
on human tonsillar B cells. We show that ligation of the B
cell antigen receptor (BCR) or CD40, two key receptors in
the initiation of antigen-specific B cell differentiation (25–
29), induces a strong upregulation of cell surface HSPGs,
specifically of CD44-HS. These HSPGs enable B cells to
selectively bind HGF, a growth factor that induces inte-
grin-dependent adhesion and migration of B cells (30, 31).
Moreover, we show that CD44-HS strongly potentiates
HGF-induced signaling in B cells.
 
Materials and Methods
 
Antibodies.
 
Mouse mAbs used were anti–pan-CD44, Hermes-3
(IgG2a [32]); anti-CD44v3, 3G5 (IgG2b; R&D Systems); anti-
HS, 10E4 (IgM; Seikagaku); anti-desaturated uronate from hep-
aritinase-treated HS (anti–
 
D
 
HS-stub), 3G10 (IgG2b; Seikagaku);
anti-HGF, 24612.111 (IgG1; R&D Systems); anti-Met, DO24
(IgG2a; Upstate Biotechnology); anti–CXC chemokine receptor
(CXCR)4, 12G5 (IgG2a; BD PharMingen); anti–syndecan-1,
1D4 (IgG1; CLB); anti–syndecan-2, 10H4 (IgG1 [33]); anti–syn-
decan-4, 8G3 (IgG1 [34]); anti–glypican-1, S1 (IgG1 [35]); an-
tiphosphotyrosine, PY-20 (IgG2b; Affiniti BioReagents, Inc.); and
IgG1, IgG2a, IgG2b, and IgM control Abs (ICN Biomedicals).
Polyclonal Abs used were rabbit anti-Met, C-12 (IgG; Santa Cruz
 
Biotechnology, Inc.); rabbit anti–Grb2-associated binder 1 (Gab1;
Upstate Biotechnology); rabbit anti–stromal cell–derived factor
(SDF)-1
 
a
 
 (PeproTech); rabbit anti-Akt (H-136; Santa Cruz Bio-
technology, Inc.); phospho-specific rabbit anti-Akt (Ser 473; New
England Biolabs, Inc.); RPE-conjugated goat anti–mouse (South-
ern Biotechnology Associates); biotin-conjugated swine anti–rab-
bit (Dako); horseradish peroxidase (HRP)-conjugated goat anti–
rabbit (Dako); and HRP-conjugated rabbit anti–mouse (Dako). In
addition, we used RPE-conjugated streptavidin (Dako).
 
B Cell Isolation and Culturing.
 
B cells were isolated from hu-
man tonsils as described previously (36). Total B cell fractions
were 
 
.
 
97% pure as determined by FACS
 
®
 
 analysis. B cells were
cultured in RPMI 1640 containing 10% FCS, 2 mM 
 
l
 
-glu-
tamine, 100 IU/ml penicillin, and 100 IU/ml streptomycin (all
from GIBCO BRL/Life Technologies). Some media were sup-
plemented with either 50 ng/ml PMA (Sigma-Aldrich), 0.002%
 
Staphylococcus aureus
 
 Cowan strain I (SAC; Calbiochem-Novabio-
chem), 1 
 
m
 
g/ml Immunobeads with covalently bound rabbit
anti–human Ig (Irvine Scientific), 100 U/ml IL-2 (Eurocetus),
100 U/ml IL-4 (Genzyme), 0.5 ng/ml IL-6 (CLB), or 25 ng/ml
IL-10 (Genzyme).
For CD40 ligation, B cells were cultured on irradiated (7,000
rads) CD40L (CD154)-transfected or, as a control, wild-type L
cells (37).
 
Cell Lines and Transfectants.
 
The Burkitt’s lymphoma cell line
Namalwa was purchased from American Type Culture Collec-
tion. The cells were cultured in RPMI 1640 (GIBCO BRL/Life
Technologies) supplemented with 10% Fetal Clone I serum (Hy-
Clone Laboratories), 10% FCS (Integro), 2 mM 
 
l
 
-glutamine, 100
IU/ml penicillin, and 100 IU/ml streptomycin (all GIBCO
BRL/Life Technologies). The Namalwa cell lines transfected
with CD44s (Nam-SM) or CD44v3-10 (Nam-V3M) were de-
scribed previously (30, 38).
 
Enzyme Treatments.
 
For enzymatic cleavage of HS, cells or
tissue sections were treated with 10 mU/ml heparitinase (
 
Fla-
vobacterium heparinum
 
, EC 4.2.2.8; ICN Biomedicals) in RPMI
1640 (GIBCO BRL/Life Technologies) at 37
 
8
 
C for 3 h. The
cleavage of HS by heparitinase was determined by the loss of cell
surface–expressed HS (mAb 10E4), and the simultaneous gain of
HS-stub expression (mAb 3G10). Chondroitinase treatment was
used as a specificity control.
 
FACS
 
®
 
 Analysis.
 
FACS
 
®
 
 analyses using a single or triple
staining technique were described previously (39, 40). For cyto-
kine binding assays, cells were incubated with saturating concen-
trations (20 nM) of recombinant human HGF or recombinant
human SDF-1
 
a
 
 (both R&D Systems) in PBS for 1 h, before the
Ab incubations. This step was followed by washing with FACS
buffer. For blocking studies, cells were incubated with 125 nM
recombinant human FGF-2 or recombinant human SDF-1
 
a
 
(both R&D Systems) in PBS at 4
 
8
 
C for 1 h, before the incuba-
tion with HGF.
 
Immunoprecipitation and Western Blot Analysis.
 
Immunoprecip-
itation and Western blotting were performed as described (39).
For the immunodepletion experiments, the lysates were immu-
noprecipitated twice and the lysate remaining after the second
immunodepletion and the immunoprecipitate obtained during
the first immunoprecipitation were analyzed by Western blotting.
 
Results
 
Expression and Regulation of HSPGs on Human B Cells.
 
We investigated the expression of HSPGs on the cell sur-
face of resting and activated human tonsillar B cells by 
1117
 
van der Voort et al.
 
means of FACS
 
®
 
 analysis, using mAb 10E4, against an
epitope on HS chains. In addition, we used mAb 3G10,
recognizing the 
 
D
 
HS-stubs that remain present on HSPG
core proteins after heparitinase treatment. HSPGs were
hardly detectable on freshly isolated tonsillar B cells. How-
ever, upon stimulation of these cells with the phorbol ester
PMA, we observed a strong induction of HSPGs (data not
shown). This observation prompted us to explore whether
HSPGs can also be induced by physiological B cell activa-
tors. Since engagement of the BCR and CD40 plays a key
role in the initiation of T cell–dependent B cell responses
and in the formation of germinal centers (GCs) (25–29),
we assessed whether activation via these receptors also leads
to HSPG upregulation. Tonsillar B cells were cultured on
CD40 ligand (CD40L)-transfected L cells or, as a control,
on wild-type L cells, in the presence or absence of BCR
stimuli (anti-Ig Abs or SAC). As is shown in Fig. 1, con-
current ligation of CD40 and the BCR induced a strong
induction of HSPGs on the B cells. Single triggering of ei-
ther the BCR or CD40 also led to enhanced HSPG ex-
pression, although the HSPG levels were lower than those
obtained upon dual receptor ligation. In contrast, stimula-
tion by various cytokines including IL-2, IL-4, IL-6, and
IL-10 did not lead to a significant induction of HSPGs
(data not shown). These data identify activation via the
BCR and CD40 as major signals for the induction of
HSPG expression on tonsillar B cells.
 
HSPGs on Activated B Cells Selectively Bind HGF.
 
HSPGs are capable of highly selective cytokine binding and
presentation (4). To explore the cytokine-binding ability
and specificity of the HSPGs expressed on activated B cells,
we tested their capacity to bind two distinct cytokines with
established heparin-binding capacity, i.e., HGF and SDF-
1
 
a
 
 (18, 41). Although they are structurally unrelated—
HGF belongs to the plasminogen-related growth factor
family (42) and SDF-1
 
a
 
 is a chemokine (43)—these cyto-
kines have both been implicated in the regulation of B cell
adhesion and migration (30, 31, 41, 43). In agreement with
the data presented in Fig. 1, culturing of tonsillar B cells on
CD40L-transfected, but not on wild-type, L cells led to a
strong induction of HS (Fig. 2 A). In parallel, these B cells
acquired a vast capacity to bind HGF (Fig. 2 A). This HGF
binding was largely dependent on HS, since 
 
.
 
80% was lost
Figure 1. Activation via the BCR and CD40 induces strong expression
of HSPGs on B cells. Tonsillar B cells were cultured on CD40L-trans-
fected L cells or wild-type L cells, in the presence or absence of BCR
stimuli, i.e., anti-Ig immunobeads (Ig) or SAC, for 0, 24, or 48 h, and an-
alyzed by FACS®. Expression of HSPGs is given as the mean fluorescence
intensity of the anti–DHS-stub staining after heparitinase treatment minus
its staining before treatment.
Figure 2. HSPGs on activated B
cells bind HGF but not SDF-1a. (A)
CD40 stimulation induced HS ex-
pression and HGF binding, but not
SDF-1 binding. Tonsillar B cells
were analyzed by FACS® for HS ex-
pression and for their capacity to
bind HGF or SDF-1a after being
cultured on CD40L-transfected L
cells or wild-type L cells for 48 h.
To determine the involvement of
HS, the cells were analyzed after
control or heparitinase treatment.
Expression of HS is given as the
mean fluorescence intensity after
staining with anti-HS mAb 10E4
minus staining with an isotype-
matched control mAb. Binding of
HGF or SDF-1a is given as the
mean fluorescence intensity of cells
that were incubated with one of the
cytokines, washed, and stained with
a cytokine-specific Ab, minus the mean fluorescence intensity of identically stained control cells. (B) Effect of CD40 stimulation on Met and CXCR4
expression. Expression of the receptor for HGF, Met, and the receptor for SDF-1a, CXCR4, on unstimulated or CD40L-stimulated tonsillar B cells was
analyzed by FACS®. Expression of Met or CXCR4 is given as the mean fluorescence intensity after staining with receptor-specific mAbs, minus the
mean fluorescence intensity after staining with an isotype-matched control mAb. 
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after heparitinase treatment of the B cells (Fig. 2 A). The
HGF that remained present on the cells after heparitinase
treatment most probably was bound to its receptor tyrosine
kinase Met, as Met was also induced by CD40 ligation (Fig.
2 B). In contrast to HGF, binding of SDF-1
 
a
 
 to the B cells
was completely independent of HS: the HSPG
 
low
 
 B cells
that were cultured on wild-type L cells had a much greater
SDF-1
 
a
 
 binding capacity than the HSPG
 
high
 
 B cells cul-
tured on CD40L-transfected L cells (Fig. 2 A). Moreover,
heparitinase treatment did not have any effect on SDF-1
 
a
 
binding. The differences in SDF-1
 
a
 
 binding between rest-
ing and activated cells were directly related to differential
expression of CXCR4, the high affinity receptor for SDF-
1
 
a
 
: expression of this receptor strongly decreased as a result
of CD40 ligation (Fig. 2 B).
 
Activated B Cells Express HSPG Forms of CD44.
 
The
above data show that, upon their activation, B cells acquire
cell surface–expressed HS chains that are capable of selec-
tive growth factor binding. This may be the consequence
of either upregulation of proteoglycan core protein(s) or
upregulation or activation of the enzymes involved in HS
synthesis. To address this issue and to identify the pro-
teoglycan core proteins carrying the HS chains, we em-
ployed mAbs against a panel of defined proteoglycan core
proteins, i.e., the syndecans-1, -2, and -4, glypican-1, and
CD44. As is shown in Fig. 3 A, B cell activation enhanced
expression of CD44 splice variants containing epitopes en-
coded by exon v3, which can be decorated with HS (39,
44). By contrast, no basal expression, or induction of the
 
distinct syndecans or glypican-1, was observed after B cell
activation via CD40 and/or the BCR (Fig. 3 A, and data
not shown).
To ensure that the CD44 isoforms expressed by activated
tonsillar B cells are indeed decorated with HS chains,
CD44 was immunoprecipitated from resting and activated
B cells and the immunoprecipitates were analyzed on
Western blot for the presence of CD44 and HS. Whereas
both unstimulated and CD40L-stimulated B cells expressed
the 90-kD “standard” isoform of CD44 (CD44s; Fig. 3 B),
activation via CD40, in addition, induced expression of a
200-kD CD44 isoform (Fig. 3 B). Upon restaining the
blot, only this 200-kD CD44 isoform was found to be
modified with HS. By its size, the CD44-HS isoform on
activated B cells resembles the HS-modified CD44v3-10
isoform expressed on Namalwa cells (Fig. 3 B), suggesting
that they are the products of similar or identical transcripts.
Since we demonstrated in Fig. 2 that the HSPGs in-
duced upon B cell activation specifically bound HGF but
not SDF-1
 
a
 
, we investigated the ability of CD44-HS to
bind HGF and SDF-1
 
a
 
. For this purpose, we employed
Namalwa B cells transfected with either the CD44-HS iso-
form CD44v3-10, or the isoform CD44s, which does not
contain an HS-attachment site (44). Indeed, as shown
in Fig. 4 A, only the Namalwa cells transfected with
CD44v3-10 expressed HS. Moreover, in contrast to HGF,
SDF-1
 
a
 
 did not bind to these cells in an HS-dependent
manner (Fig. 4 B). Furthermore, in contrast to the heparin-
binding growth factor FGF-2, SDF-1
 
a
 
 did not compete
Figure 3. CD40 stimulation induces expression of CD44-HS on ton-
sillar B cells. (A) CD44-HS, but not syndecan-1, is induced by CD40
stimulation. Expression of syndecan-1 or CD44v3 by tonsillar B cells cul-
tured on CD40L-transfected L cells or wild-type L cells for 0, 24, or 48 h
was analyzed by FACS®. Expressions are given as the mean fluorescence
intensity after staining with anti–syndecan-1 or anti-CD44v3, minus the
staining with isotype-matched control mAbs. (B) CD44v3 isoform(s) on
CD40-activated B cells are decorated with HS. CD44 was immunopre-
cipitated from tonsillar B cells that had been cultured on wild-type L cells
or CD40L-transfected L cells for 48 h, and immunoblotted with anti–
pan-CD44 (left), or with anti–DHS-stub (right). To allow the detection
of DHS-stubs, the cells had been treated with heparitinase before immu-
noprecipitation. Namalwa B cells transfected with the HSPG CD44v3-10
(Nam-V3M) were used as a positive control. 
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with HGF for binding to the cells, even at concentrations
exceeding those of FGF-2 by more than a factor of 10 (Fig.
4 C). Taken together, these results indicate that ligation of
CD40 on tonsillar B cells induces the expression of CD44-
HS, most likely the CD44v3-10 isoform. This CD44 iso-
form is capable of selectively recruiting HGF to the B cell
surface.
 
Cell Surface HSPGs Regulate Met Signaling in B Cells.
 
The above data suggest a role for HSPGs, specifically
CD44-HS, in the regulation of HGF/Met signaling. To
address this hypothesis, we employed Met
 
1
 
 Namalwa B
cells transfected with either a CD44-HS isoform (CD44v3-
10), or, as a control, with a CD44 isoform that cannot be
decorated with HS (CD44s) (39). Upon HGF stimulation,
a strong phosphorylation of Met was induced in the cells
expressing CD44-HS, whereas phosphorylation in the cells
expressing CD44s was weak (Fig. 5 A). HS moieties deco-
rating CD44 were responsible for the strongly enhanced
Met phosphorylation in the cells carrying CD44-HS, as he-
paritinase treatment reduced the HGF induced phosphory-
lation to the control level observed in the cells expressing
CD44s (which lack HS) (Fig. 5 A). The strong potentiation
of Met signaling by HS on the B cell surface was not
present only at the level of receptor phosphorylation: as is
show in Fig. 5 B, upon HGF stimulation a broad band rep-
resenting (a) hyperphosphorylated protein(s) of 
 
z
 
110–120
kD was detected in the lysates of B cells expressing CD44-
HS, but not in those expressing CD44s. Like the Met
phosphorylation, this hyperphosphorylation was HS de-
pendent (Fig. 5 B). By performing immunodepletion ex-
periments, we observed that the broad band was actually
composed of (at least) two bands (Fig. 5 C). The lower of
these bands was identified as Gab1 (Fig. 5 C), an adapter
 
protein that can associate with the cytoplasmic docking site
of Met (45). Indeed, in anti-Gab1 immunoprecipitates, we
detected a phosphorylated protein of 
 
z
 
145 kD which
probably represents Met (Fig. 5 C). In addition to Gab1
phosphorylation, a strongly enhanced activation of Akt,
also referred to as protein kinase B (PKB), was found upon
HGF stimulation in cells expressing CD44-HS compared
with cells expressing CD44s (Fig. 5 D). Again, enhanced
Akt activation was HS dependent, as it could be abrogated
by heparitinase treatment of the cells expressing CD44-HS
but not CD44s (Fig. 5 D). Taken together, these data dem-
onstrate that CD44-HS is capable of regulating HGF/Met
signaling in B cells in an HS-dependent fashion.
 
Discussion
 
HS proteoglycans are involved in regulating the growth,
migration, and differentiation of epithelial cells and fibro-
blasts (1, 3, 7–9). During these processes, HSPGs immobi-
lize and oligomerize cytokines and present them to their
high affinity receptors (5, 46–48). In this way, HSPGs cre-
ate niches in the microenvironment and regulate cytokine
responses. Since a large number of cytokines involved in
lymphoid tissue homeostasis or inflammation contain po-
tential HS-binding sites, HSPGs presumably also play im-
portant roles in the regulation of the immune response.
However, the expression and function of HSPGs on the
cell surface of lymphocytes, as well as within the extracel-
lular matrix of the lymphoid tissues, have thus far re-
mained largely unexplored. In this study, we investigated
the regulation and function of HSPGs on human B cells.
We demonstrate that expression of HSPGs on human B
cells is dynamic and that HSPGs are capable of selective
Figure 4. HGF, but not SDF-1a, binds to CD44v3-10 (CD44-HS). (A) Namalwa B cells stably transfected with CD44v3-10 (Nam-V3M) express
HS, whereas those transfected with CD44s (Nam-SM) do not. (B) Namalwa B cells stably transfected with CD44v3-10 (Nam-V3M) express Met and
CXCR4 and show HS-dependent binding of HGF but not of SDF-1a. Nam-V3M cells were analyzed by FACS® for their expression of HS, Met, or
CXCR4. In addition, their capacity to bind HGF or SDF-1a is shown. To determine the involvement of HS, the cells were analyzed after control or he-
paritinase treatment. Expression of HS, Met, or CXCR4 is given as the mean fluorescence intensity after staining with specific mAbs minus the mean flu-
orescence intensity after staining with an isotype-matched control mAb. Binding of HGF or SDF-1a is given as the mean fluorescence intensity of cells
that were incubated with one of the cytokines, washed, and stained with a cytokine-specific Ab, minus the mean fluorescence intensity of identically
stained control cells. (C) HGF binding to CD44v3-10 is cross-blocked by FGF-2 but not by SDF-1a. HGF binding to Namalwa CD44v3-10 transfec-
tants was analyzed by FACS® as described above. Before the incubation with HGF, the cells were incubated with a range of concentrations of either
FGF-2 or SDF-1a. 
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cytokine binding and regulation of cytokine-induced sig-
naling.
We observed that freshly isolated tonsillar B cells express
low levels of HSPGs but that single or concurrent ligation
of the BCR and CD40 induced a strong expression of
HSPGs on the B cell surface (Fig. 1). These observations
for the first time show that B cell triggering by physiologi-
cal stimuli has a profound effect on their HSPG expression
and suggest that B cells use cell surface HSPGs as a means
of controlling their cytokine-binding capacity and respon-
siveness. To explore this hypothesis, we analyzed the bind-
ing of the cytokines HGF and SDF-1
 
a
 
 to HSPGs on acti-
vated B cells. These cytokines were selected because they
bind heparin, a heavily sulfated HS proteoglycan, with sim-
ilar affinities (41, 49, 50). Moreover, although HGF and
SDF-1
 
a
 
 are structurally unrelated, they have both been
implicated in the regulation of B cell adhesion and migra-
tion (30, 31, 51, 52). HGF is a 90-kD cytokine that in-
duces complex responses in target cells, e.g., stimulation of
motility, growth, and morphogenesis, by binding to the re-
ceptor tyrosine kinase Met (53–58). HGF is essential for
vertebrate development, since knockout of the 
 
HGF
 
 or
 
Met
 
 genes is lethal, causes abnormal development of the
liver and placenta, and disrupts the migration of myogenic
precursors to the limb buds (59–61). Other studies suggest
important roles for HGF in tissue regeneration and in tu-
mor growth, invasion, and metastasis (53, 62–64). The
CXC chemokine SDF-1 was originally identified as a pre-
B cell growth-stimulating factor (65) and, more recently,
has been implicated in a variety of processes, including he-
matopoiesis, cerebellar and vascular development, and car-
diogenesis, by activating its receptor CXCR4 (66–69).
SDF-1
 
a
 
 is a potent chemoattractant for hematopoietic pro-
genitors, and induces migration of naive and memory, but
not GC, B cells (43, 52, 69, 70).
We observed that the inducibly expressed HSPGs on
CD40-activated B cells are capable of binding large quanti-
ties of HGF, but not SDF-1
 
a
 
. Instead, B cell activation re-
sulted in a strongly decreased binding of SDF-1
 
a
 
 to the B
cells (Fig. 2 A). This could be explained by the observation
that CXCR4, the SDF-1
 
a
 
 receptor, was downregulated in
response to CD40 triggering, in analogy to BCR-induced
downregulation of CXCR4 (71; Fig. 2 B). The finding
that HS moieties on B cells do not bind SDF-1
 
a
 
 was fur-
ther corroborated by our observation that SDF-1
 
a
 
, unlike
the heparin-binding cytokine FGF-2, does not compete
with HGF for HSPG binding (Fig. 4 C). Hence, upon
their activation via the BCR and CD40, B cells not only
gain expression of the HGF receptor Met (30) (Fig. 2 B),
but also acquire the appropriate HSPGs, i.e, HSPGs with
the capacity to bind large quantities of HGF. Thus, unlike
interactions with heparin, the interaction between cyto-
kines and the natural HSPGs that are induced during B cell
activation appear to be highly selective, suggesting that
Figure 5. CD44-HS promotes
HGF/Met signaling in B cells in
an HS-dependent fashion. (A)
CD44-HS promotes HGF-
induced  tyrosine phosphoryla-
tion of Met. Namalwa B cells,
stably transfected with either
CD44v3-10 (v3), which is HS
decorated, or CD44s (s), were
treated with heparitinase, as in-
dicated, and subsequently stimu-
lated with HGF. Anti-Met
immunoprecipitates were immu-
noblotted with antiphosphoty-
rosine (PY-20, top), or with anti-
Met (bottom). (B) CD44-HS
promotes HGF-induced tyro-
sine phosphorylation of proteins
downstream of Met. An immu-
noblot of total cell lysates pre-
pared from cells treated as
described in A was stained with
antiphosphotyrosine. The arrow
indicates (a) highly phosphory-
lated protein(s) at 115–120 kD.
(C) HGF-induced Gab1 phos-
phorylation is enhanced in the
presence of CD44-HS. An im-
munoblot of immunodepleted
Namalwa CD44v3-10 cell lysates
(left) or their corresponding im-
munoprecipitates (right) is shown. Immunoprecipitation was performed with anti-Gab1 or control mAbs (C) as indicated. The blots were stained with an-
tiphosphotyrosine (anti-PY, top) or anti-Gab1 (bottom). The arrowhead indicates a band probably representing coimmunoprecipitated Met, while the
thin and thick arrows indicate an unidentified protein of z115 kD and Gab1, respectively. (D) CD44-HS promotes HGF-induced activation of Akt/
PKB. Control or heparitinase-treated cells were incubated with HGF for 0, 2, or 10 min as indicated. Total cell lysates from the transfectants described in
A were immunoblotted with anti–phospho-Akt (top) or anti-Akt (bottom). 
1121
 
van der Voort et al.
 
HSPGs contribute an additional level of specificity to B
cell–cytokine interactions and may coregulate B cell differ-
entiation. Selectivity of HSPG–protein interactions has also
been observed in other biological systems, including blood
coagulation and embryonic development (2–4, 9). It is de-
termined by the structural modifications of the HS chains,
which take place within the Golgi complex, as well as by
the nature of the core protein (4, 18).
HSPGs consist of HS chains covalently attached to a core
protein. Ligation of CD40 resulted in a strong induction of
cell surface–expressed CD44 splice variants containing the
domain encoded by exon v3 (Fig. 3 A). This domain con-
tains a consensus motif for HS attachment (39, 44), and we
indeed confirmed that CD44 isoforms on activated B cells
are decorated with HS (Fig. 3 B). The relative molecular
mass of the HSPG form of CD44 on activated B cells was
indistinguishable from that of a CD44v3-10 isoform ex-
pressed by Namalwa cells, suggesting that they are products
of similar or identical transcripts (Fig. 3 B). Although we
cannot exclude a contribution of other (unknown) core
proteins, our findings identify CD44 as an important cell
surface HSPG on activated B cells. As of yet, data on the
expression and function of HSPGs in lymphocytes are
scarce. The HSPG syndecan-1 can be expressed by human
plasma cells, myeloma cells, and Reed-Sternberg cells of
classical Hodgkin’s disease (72–74), and syndecan-4 expres-
sion has been demonstrated in mouse B cells (75). Apart
from a possible role in growth factor presentation, analo-
gous to that observed for CD44-HS in this study, synde-
can-1 and -4 may be important mediators of cell–cell adhe-
sion since their transfection to B lymphoblastoid cell lines
results in cell spreading and aggregation (76, 77).
Incubation of HGF with heparin or HS-derived oli-
gosaccharides has been reported to promote phosphoryla-
tion of the HGF receptor Met (15). This prompted us to
explore the impact of CD44-HS expression on HGF-
induced signal transduction. Interestingly, we observed that
the autophosphorylation of Met, as well as the phosphory-
lation of the kinase Akt/PKB, and of two proteins of 110–
120 kD is strongly promoted by expression of CD44-HS at
the B cell surface (Fig. 5). Immunodepletion experiments
indicated that the smaller of the two proteins represents
Gab1, an adapter protein that can associate with Met (45;
Fig. 5 C). The other hyperphosphorylated protein might
represent p120-Cbl, a protein tyrosine kinase that partici-
pates in signal transduction via receptor tyrosine kinases,
and that has been implicated in the regulation of integrin
activation (78, 79). This is of particular interest, since stim-
ulation of B cells with HGF results in enhanced integrin-
dependent adhesion (see below).
Our observations suggest a scenario in which B cells,
upon their activation by antigen and T cells, become insen-
sitive to the migration-promoting activity of SDF-1
 
a
 
 as a
result of downregulation of CXCR4. At the same time,
they acquire the receptor tyrosine kinase Met (30) as well
as HSPG, viz. CD44-HS, which allow them to selectively
recruit HGF to the B cell surface, resulting in efficient
HGF/Met signaling. We have previously shown that HGF
 
is produced by follicular dendritic cells and enhances inte-
grin-dependent adhesion of B cells to fibronectin and vas-
cular cell adhesion molecule (VCAM)-1. Hence, activation
of the HGF/Met pathway may strengthen B cell adhesion,
specifically to follicular dendritic cells, which is mediated
by 
 
a
 
4
 
b
 
1/VCAM-1 (80). Interestingly, apart from estab-
lishing physical contact, outside-in signaling via 
 
a
 
4
 
b
 
1 pre-
sumably contributes to the B cell selection process in the
GC by inhibiting apoptosis of B cells (36, 40). Since both
integrin engagement and Met stimulation may lead to acti-
vation of Akt/PKB, a pathway reported to suppress apop-
tosis (81), it will be of interest to explore the collaborative
effects of integrin and Met signaling on B cell survival.
In conclusion, our data demonstrate that the BCR
and CD40 control the expression of HSPGs, specifically
CD44-HS, on B cells. By selectively binding HGF to the B
cell surface, these HSPGs act as functional coreceptors for
HGF promoting signaling through Met, which suggests a
role for these HSPGs in the regulation of antigen-specific B
cell differentiation.
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